Blueprint Medicines (BPMC) to Release Quarterly Earnings on Thursday

Blueprint Medicines (NASDAQ:BPMC) is set to issue its quarterly earnings data before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of ($1.65) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, topping the consensus estimate of ($2.04) by $0.22. The business had revenue of $71.96 million during the quarter, compared to analyst estimates of $67.34 million. Blueprint Medicines had a negative return on equity of 191.56% and a negative net margin of 203.30%. The company’s quarterly revenue was up 85.5% on a year-over-year basis. During the same period last year, the business posted ($2.65) earnings per share. On average, analysts expect Blueprint Medicines to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Blueprint Medicines Trading Up 1.9 %

NASDAQ:BPMC opened at $92.29 on Wednesday. The firm has a market cap of $5.65 billion, a PE ratio of -11.04 and a beta of 0.63. The stock has a fifty day moving average price of $90.36 and a 200 day moving average price of $78.32. Blueprint Medicines has a 12-month low of $43.89 and a 12-month high of $101.00. The company has a current ratio of 3.76, a quick ratio of 3.66 and a debt-to-equity ratio of 1.60.

Insider Transactions at Blueprint Medicines

In other news, Director Jeffrey W. Albers sold 25,000 shares of Blueprint Medicines stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $81.91, for a total transaction of $2,047,750.00. Following the transaction, the director now owns 176,050 shares in the company, valued at $14,420,255.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Blueprint Medicines news, EVP Tracey L. Mccain sold 5,194 shares of the business’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.69, for a total value of $471,043.86. Following the transaction, the executive vice president now owns 60,498 shares in the company, valued at $5,486,563.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey W. Albers sold 25,000 shares of the business’s stock in a transaction dated Thursday, January 25th. The shares were sold at an average price of $81.91, for a total value of $2,047,750.00. Following the completion of the transaction, the director now owns 176,050 shares in the company, valued at approximately $14,420,255.50. The disclosure for this sale can be found here. Insiders have sold 117,289 shares of company stock valued at $10,361,913 over the last three months. Company insiders own 3.88% of the company’s stock.

Analyst Upgrades and Downgrades

BPMC has been the subject of a number of research analyst reports. Stifel Nicolaus upped their price target on Blueprint Medicines from $95.00 to $97.00 and gave the company a “buy” rating in a report on Tuesday, January 9th. Barclays increased their price objective on Blueprint Medicines from $58.00 to $70.00 and gave the company an “equal weight” rating in a report on Tuesday, February 13th. JMP Securities reissued a “market outperform” rating and issued a $114.00 price objective on shares of Blueprint Medicines in a report on Wednesday, April 10th. Wedbush reissued an “outperform” rating and issued a $97.00 price objective on shares of Blueprint Medicines in a report on Monday, February 5th. Finally, Citigroup increased their price objective on Blueprint Medicines from $54.00 to $65.00 and gave the company a “sell” rating in a report on Friday, February 16th. Four investment analysts have rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $85.43.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.